Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:BXLT
- CUSIP: N/A
- Web: www.baxalta.com/
- 50 Day Moving Avg: $46.02
- 200 Day Moving Avg: $46.02
- 52 Week Range: $37.44 - $46.52
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 18.12
- P/E Growth: 0.00
- Net Margins: 9.37%
- Return on Equity: 14.28%
- Return on Assets: 4.62%
Frequently Asked Questions for Baxalta (NYSE:BXLT)
What is Baxalta's stock symbol?
Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."
How were Baxalta's earnings last quarter?
Baxalta Inc (NYSE:BXLT) issued its quarterly earnings data on Thursday, April, 28th. The company reported $0.47 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.46 by $0.01. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.47 billion. Baxalta had a net margin of 9.37% and a return on equity of 14.28%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 earnings per share. View Baxalta's Earnings History.
Who are some of Baxalta's key competitors?
Some companies that are related to Baxalta include Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Strongbridge Biopharma PLC (SBBP), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL) and Peregrine Pharmaceuticals (PPHM).
How do I buy Baxalta stock?
Shares of Baxalta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxalta's stock price today?
MarketBeat Community Rating for Baxalta (NYSE BXLT)MarketBeat's community ratings are surveys of what our community members think about Baxalta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Baxalta stock can currently be purchased for approximately $46.02.
Consensus Ratings for Baxalta (NYSE:BXLT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Baxalta (NYSE:BXLT)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/6/2016||Cowen and Company||Reiterated Rating||Buy||N/A|
|12/9/2015||Barclays PLC||Boost Price Target||Equal Weight||$38.00 -> $40.00||N/A|
|10/27/2015||William Blair||Reiterated Rating||Buy||N/A|
Earnings History for Baxalta (NYSE:BXLT)Earnings History by Quarter for Baxalta (NYSE BXLT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/28/2016||Q116||$0.46||$0.47||$1.47 billion||$1.50 billion||View||N/A|
|2/16/2016||Q415||$0.56||$0.57||$1.71 billion||$1.80 billion||View||N/A|
|10/29/2015||Q315||$0.49||$0.56||$1.51 billion||$1.60 billion||View||Listen|
|7/30/2015||Q215||$0.50||$0.40||$1.41 billion||$1.47 billion||View||N/A|
Earnings Estimates for Baxalta (NYSE:BXLT)
Current Year EPS Consensus Estimate: $2.19 EPS
Next Year EPS Consensus Estimate: $2.54 EPS
Current Dividend Information for Baxalta (NYSE:BXLT)
|Most Recent Dividend:||7/1/2016|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||0.00% (Based on This Year's Estimates)|
0.00% (Based on Next Year's Estimates)
Dividend History by Quarter for Baxalta (NYSE BXLT)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Baxalta (NYSE:BXLT)Insider Trades by Quarter for Baxalta (NYSE:BXLT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/24/2016||Albert P L Stroucken||Director||Sell||5,660||$39.98||$226,286.80|| |
|2/25/2016||Blake E Devitt||Director||Buy||5,900||$39.17||$231,103.00|| |
Headline Trends for Baxalta (NYSE:BXLT)
Latest Headlines for Baxalta (NYSE:BXLT)
Baxalta (BXLT) Chart for Friday, September, 22, 2017